Severe midaortic syndrome: a stepwise approach to treatment with drug-eluting balloons: a case report

Peter Zartner*, Christopher Hart, and Martin B.E. Schneider

Department of Cardiology, German Paediatric Heart Center, Arnold Janssen Str. 29, 53757 Sankt Augustin, Germany

Received 23 September 2018; accepted 4 February 2019; online publish-ahead-of-print 25 February 2019

Background
Severe forms of the midaortic syndrome cause persistent arterial hypertension and can lead to angina abdominalis. Untreated, morbidity, and mortality are significant. In addition to palliation through bypass surgery, few other therapeutic approaches lead to a long-term relief. Drug-eluting balloons (DEB) covered with paclitaxel, a cytostatic drug, have proven to be effective in bifurcational lesions and for in-stent stenoses in coronary arteries.

Case summary
In a 15-year-old girl with severe midaortic syndrome and multiple collateral arteries, four interventional balloon dilatations with DEB of increasing diameters resolved the stenosis within 8 months. After a procedure free interval of now 2.7 years, the anatomical and the physical condition of the patient remained unchanged.

Discussion
This stepwise approach, with a low procedural risk and a lasting result may justify further investigations into this combined treatment.

Keywords
Coarctation • Arterial hypertension • Non-surgical interventional treatment • Congenital heart disease • Case report • Drug-eluting balloon

Introduction
Interventional dilation with drug-eluting balloons (DEB) is an established therapeutic option in coronary and peripheral arterial disease in adults.1 With successful results in adults, the use in paediatric patients with congenital stenosis has begun. Besides a few clinical trials in pulmonary vein stenosis, only a single case with the use of a paclitaxel eluting balloon in a child with Takayasu’s disease and renal artery stenosis has been published.2

The midaortic syndrome is a rare diagnosis and is defined as segmental narrowing of the proximal abdominal aorta. It can be acquired or congenital. The reduced blood perfusion to the renal arteries causes severe renovascular hypertension. Effective therapeutic options are surgical with different modifications of aortoarterial bypass...
grafs\textsuperscript{4,5} or interventional with the implantation of stents,\textsuperscript{6,7} but results are not always satisfactory, particularly on long-term follow-up.

### Timeline

| Date       | Procedures                                      | Time difference |
|------------|------------------------------------------------|-----------------|
| 10 February 2015 | Suspected diagnosis because of syncope, episodes of headache, nose bleeding, and blood pressure difference between arms and legs. Diagnosis by echocardiography with left ventricular hypertrophy and a narrow long segment of the abdominal aorta proximal to and involving the renal arteries. | Age 15 years |
| 12 February 2015 | Dilation with 7 mm drug-eluting balloons (DEB) | 2 days          |
| 19 April 2015 | Dilation with 8 mm DEB | 9.4 weeks       |
| 22 June 2015 | Dilation with 10 mm DEB | 9.1 weeks       |
| 28 October 2015 | Dilation with 12 mm DEB | 18.2 weeks      |
| 20 June 2018 | Control magnetic resonance imaging demonstrated no evidence of recurrence of stenosis. The blood pressure was 139/64 mmHg at the right arm and 127/65 mmHg at the right leg under therapy with atenolol and amlopidine. | 2.64 years |

### Case presentation

A 15-year-old female patient (bodyweight 50 kg, height 160 cm) presented with syncope. Severe arterial hypertension was diagnosed (178/147 mmHg left arm, 102/83 mmHg left leg). She reported previous episodes of exercise independent headaches and nose bleeds. Auscultation revealed no cardiac murmurs, but an accentuated second heart sound and reduced pulses in the lower limbs. There were no clinical signs to suggest Alagille or William’s syndrome or clinical evidence of neurofibromatosis. Blood tests showed normal inflammatory markers and normal creatinine. The urine dip showed no markers for blood or protein. No regular medication was taken at the time she presented. The electrocardiogram showed normal sinus rhythm, no significant signs of left ventricular (LV) hypertrophy or abnormal repolarization. Echocardiography detected a severe concentric LV hypertrophy (14 mm diastolic septal diameter, 15 mm
diastolic diameter of the LV posterior wall) and a long hypoplastic segment in the abdominal aorta with massive arterial collateralization. Cardiac catheterization confirmed the diagnosis of a midaortic syndrome with a minimum diameter of <1.5 mm and a gradient of 50 mmHg between the aortic arch and the femoral arteries (Figure 1A). The narrow part began directly under the diaphragm above the truncus coeliacus and continued down to the bifurcation of the arterial iliacs including the renal arteries, with reversed flow in the caudal aorta up to the renal arteries. Because of the extraordinary length of the hypoplastic segment of 23 cm, we decided for a stepwise interventional therapy with a paclitaxel covered balloon. No additional computed tomography scan or magnetic resonance imaging (MRI) was performed. Consultation with our surgeon, supported the interventional approach. The proposed procedure was reviewed and approved by our institutional review board, extensively discussed with the patient’s family, and informed consent was obtained before proceeding.

After balloon interrogation of the long stenotic abdominal aorta using a 6 × 20 mm Tyshak balloon (NuMED Inc., Hopkinton, NY, USA) to differentiate between rigid stenosis and hypoplastic parts, serial balloon dilation with a 7 × 40 mm paclitaxel covered In.Pact balloon (Medtronic, Minneapolis, MN, USA) (3 μg/mm² Paclitaxel on the balloon) was performed (Figure 1B) from end to end of the stenosis. Planned redilations, to stepwise improve the aortic compliance and reduce the risk of dissection, were performed after 2, 4, and 8 months with Elutax balloons ranging from 8 mm to 12 mm diameter (Aachen Resonance, Düsseldorf, Germany) (2 μg/mm² Paclitaxel). At the end of the last interventional procedure, a mild endothelial lesion at the former narrowest point of the aorta was noticed (Figure 1C). This lesion healed and after 2.7 years MRI showed a stable and adequate result (Figure 1D). Today the girl is in unrestricted physical condition. The blood pressure has markedly improved (139/64 mmHg right arm and 127/65 mmHg right leg) under therapy with atenolol and amlopidine.

The patient and patient’s family consented to the publication of this case’s history and the images presented.

### Discussion

The midaortic syndrome is rare, but its severe form, with involvement of the renal arteries, is associated with significant morbidity and mortality.\textsuperscript{8} The results of routine measurement of the blood pressure in children should raise suspicion. Because of the non-causal treatment using antihypertensive drug combinations and poor long-term results in endovascular intervention, surgical treatment is widely accepted as the treatment of choice.\textsuperscript{6,5} However, the implantation of aortoaoctic bypass can become a very complex operation with a high intraoperative risk\textsuperscript{5} frequently followed by the need for reinterventions.

If the midaortic syndrome is interpreted as a local aortic wall disease, a combined medical and endovascular treatment might be a reasonable therapeutic option. Drug-eluting balloons and stents have proven to be safe and effective in coronary artery diseases. Paclitaxel, a cytostatic drug, which is lipophilic, anti-proliferative and irreversibly stops the cell division between meta- and Ana-phase is widely used
to cover DEB. In children some reports showed a minor and normally tolerable drug-toxicity of paclitaxel after local therapy.\textsuperscript{2,10}

In our patient, the hypoplastic segment of the aorta was very long and included all origins from the coeliac trunk to the iliac vessels. Survival was only possible because of massive collateralization. Using stents in this setting, overstenting of nearly all side branches would have been unavoidable. Surgical therapy with an aortic bypass graft of this long segment would have generated a high risk because of endangered vascular supply of all abdominal organs. Endovascular treatment with a DEB to enlarge the aortic diameter and reduce the risk for re-stenoses was seen as the best therapeutic option in this setting. As the initial result was promising, repeated re-dilations with a step-wise increasing diameter of the DEB were justified.

The latest measured residual gradient of <10 mmHg could not prevent from a persistent arterial hypertension as known from late diagnosed coarctation, so antihypertensive medication was required.

**Figure 1** (A) Initial presentation of the abdominal aorta with subtotal occlusion caused by a 1.7 mm catheter passing through the stenosis. There is a massive collateralization and only minimal contrast opacification of the right renal artery. The white arrow marks the upper entrance to the tubular coarctation of the abdominal aorta, and the black arrows mark the course of the left and right renal artery, if visible. (B) Anatomy after the first dilation with a Paclitaxel covered balloon. (C) After the fourth intervention using a 12 mm drug-eluting balloon an endothelial lesion and intramural contrast was noted (white asterisk). (D) Magnetic resonance imaging at latest follow-up 2.7 years after this last intervention shows an unobstructed aorta without collateralization.

**Conclusion**

This is a single case experience with an intervention-free clinical follow-up and an adequate local result. Repeated balloon dilations with paclitaxel eluting balloons have demonstrated to be an effective and safe therapeutic option in this patient with a severe and long segment midaortic syndrome. This treatment needs to be applied in comparable situations to better judge its value for similar patients.

**Supplementary material**

Supplementary material is available at European Heart Journal - Case Reports online.

Slide sets: A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data.
Consent: The author(s) confirm that written consent for submission and publication of this case report including image(s) and associated text has been obtained from the patient in line with COPE guidance.

Conflict of interest: none declared.

References

1. Windecker S, Kolh P, Alfonso F, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappenberger L, Kaushni S, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Souto Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Widimsky A. 2014 ESC/EACTS Guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35:2541–2619.

2. Mueller GC, Dodge-Khatami A, Weil J. First experience with a new drug-eluting balloon for the treatment of congenital pulmonary vein stenosis in a neonate. Cardiol Young 2010; 20:455–458.

3. Hecht T, Esmaeili A, Behnke-Hall K. Balloon angioplasty of the bilateral renal arteries by Takayasu arteritis with a paclitaxel-eluting balloon. Cardiol Young 2015; 25:1431–1434.

4. Kim SM, Jung JM, Han A, Min S-I, Lee T, Ha J, Kim SJ, Min S-K. Surgical treatment of middle aortic syndrome with Takayasu arteritis or midaortic dysplastic syndrome. Eur J Vasc Endovasc Surg 2015; 50:206–212.

5. Hetzer R, Abi D, Miera O, Solowjova N, Schulz A, Javier MF, Delmo Walter EM. Extraanatomic bypass technique for the treatment of midaortic syndrome in children. Ann Thorac Surg 2013; 86:183–189.

6. Brzezinska-Rajszys G, Qureshi SA, Kieszek J, Zubrzycka M, Kosciesza A, Kubicka K, Tynan M. Middle aortic syndrome treated by stent implantation. Heart 1999; 81:166–170.

7. Kim JT, Lee M, Kim YS, Yoon YH, Baek WK. Thoracic endovascular stent graft repair of middle aortic syndrome. Ann Thorac Surg 2016; 102:e233–e235.

8. Rumman PK, Nickel C, Matsuda-Abedini M, Lorenzo AJ, Langlois V, Radhakrishnan S, Amaral J, Mertens L, Parekh RS. Disease beyond the arch: a systematic review of middle aortic syndrome in childhood. Am J Hypertens 2015; 28:833–846.

9. Kim HB, Vakili K, Modi BP, Ferguson MA, Guillot AP, Potanos KM, Prabhu SP, Fishman SJ. A novel treatment for the midaortic syndrome. N Engl J Med 2012; 367:2361–2362.

10. Muller MJ, Krause U, Paul T, Schneider HE. Serum levels after everolimus-stent implantation and paclitaxel-balloon angioplasty in an infant with recurrent pulmonary vein obstruction after repaired total anomalous pulmonary venous connection. Pediatr Cardiol 2011; 32:1036–1039.